FLT3 mutation is found in about 30% of acute myeloid leukemia (AML) patients and is
associated with a poor prognosis. Several FLT3 inhibitors are undergoing investigation …

Acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like
Tyrosine kinase 3 (FLT3) gene is associated with high risk of relapse and poor clinical …

Introduction: Mutations of the FLT3 gene are among most common genetic abnormalities
occurring in acute myeloid leukemia (AML) and are associated with dismal prognosis …

Abstract Treatment of acute myeloid leukemia (AML) remains challenging with many
patients harboring unfavorable prognostic parameters such as FLT3 internal tandem …

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at
high frequency in acute myeloid leukemia (AML), being detected in> 30% of patients at …

FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute
myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but …

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular
abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse …

Activating mutations of the protein tyrosine kinase (PTK) FLT3 can be found in approximately
30% of patients with acute myeloid leukemia (AML), thereby representing the most frequent …

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3
mutations were discovered to have a role in AML. Several FLT3 inhibitors have been …

More than 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating
mutation in FMS-like tyrosine kinase-3 (FLT3). The most common type, internal tandem …